Molecular profiling of tumor cells persisting after neo-adjuvant chemotherapy for triple-negative breast cancer showed amplifications of MYC(54%) and MCL-1(35%) [61]. This evidence concerns the gene MCL1 and triple-negative breast carcinoma.